September 10, 2015 – FDA requires Janssen to add new information to Invokana warning labels regarding an increased risk of bone fractures after several clinical trials confirmed that fractures were more likely in patients treated with canagliflozin (the active ingredient in Invokana).
2015 – Janssen required to add to warning labels
Announcement Date: September 10, 2015